Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

VELCADE in Combination With Idarubicin and Cytosine Arabinoside in Patients With Acute Myelogenous Leukemia

This study has been completed.
Millennium Pharmaceuticals, Inc.
Information provided by:
Massachusetts General Hospital Identifier:
First received: July 19, 2007
Last updated: September 23, 2010
Last verified: September 2010
The primary objective of this study is to establish the maximally tolerated dose of VELCADE that can be administered with idarubicin and cytarabine in patients with AML. The secondary objectives of this study are assessment of efficacy, safety, and pharmacokinetics of Velcade when combined with Cytarabine and idarubicin. Various molecular markers associated with response to Velcade, cytarabine, and idarubicin will be explored by utilizing microarray analyses. The study endpoints are maximum tolerated dose and response to treatment.

Condition Intervention Phase
Drug: velcade
Drug: Idarubicin
Drug: Cytarabine
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase I Dose Escalating Trial of VELCADE (PS-341) in Combination With Idarubicin and Cytosine Arabinoside in Patients With Acute Myelogenous Leukemia

Resource links provided by NLM:

Further study details as provided by Massachusetts General Hospital:

Estimated Enrollment: 36
Study Start Date: July 2003
Primary Completion Date: September 2005 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients must be 18 years or older.
  • Unequivocal histologic diagnosis of AML (>20% blasts in the blood and/or bone marrow based on the WHO and/or FAB classifications as described in Appendix 9.3), excluding M3 (acute promyelocytic leukemia).
  • For patients less than 60, disease must have previously achieved CR and then relapsed (>20% blasts in the blood and/or bone marrow based on the WHO and/or FAB classifications as described in Appendix 9.3), excluding M3 (acute promyelocytic leukemia).). These patients must have a period of remission of >3 months (beginning with the time when the ANC >1,500/ul, platelets >100,000/ul and < 5% marrow blasts are present).
  • Patients 60 years of age or older may have relapsed disease or may have previously untreated AML (>20% blasts in the blood and/or bone marrow based on the WHO and/or FAB classifications as described in Appendix 9.3), excluding M3 (acute promyelocytic leukemia).
  • Patients may have prior myelodysplasia. Patients may have prior treatment for myelodysplasia.
  • Patients may have had prior chemotherapy for another malignancy or an antecedent hematologic disorder such as myelodysplasia.
  • Patients must have an ECOG performance status 0-3.
  • Patients must have all of the following pretreatment laboratory values within 21 days of enrollment: total bilirubin <= 1.5 X the upper limit of normal (ULN), ALT and AST <= 2.5 X the ULN, creatinine <= 2.0 mg/dl.
  • Male patients need to use an appropriate method of barrier contraception during the study.
  • Female patients must be post-menopausal, surgically sterilized, or willing to use acceptable methods of birth control (i.e. a hormonal contraceptive, an intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study.
  • Patients must give voluntary written informed consent before performance of any study-related procedure not part of normal medical care.

Exclusion Criteria:

  • If less than 60 years old, patient has received chemotherapy within the last three months (90 days).
  • Patients with untreated AML < 60 years old.
  • Other active malignancy (with the exception of basal and squamous cell skin cancer) at the time of study entry.
  • Patient has hypersensitivity to boron or mannitol
  • Severe pulmonary or cardiac disease.
  • History of congestive heart failure or ejection fraction < 40%.
  • Patient had a myocardial infarction within 6 months of enrollment or has New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities.
  • Patients with M3 AML (acute promyelocytic leukemia) by FAB or WHO as described in 9.3.
  • Patients with HIV infection.
  • Patients with known active hepatitis B or C.
  • Patients with known central nervous system leukemia. A lumbar puncture is not required unless CNS involvement is clinically suspected.
  • Patients who are pregnant or breast feeding.
  • Patients with major surgery within the 4 weeks prior to trial enrollment.
  • Patients with ³ Grade 2 peripheral neuropathy within 21 days before enrollment.
  • Patients with an uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia. If the condition becomes controlled, the patient may become eligible.
  • Patients with any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00505700

United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Beth Israel/ Deaconess Medical Center
Boston, Massachusetts, United States, 02115
Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02115
Sponsors and Collaborators
Massachusetts General Hospital
Millennium Pharmaceuticals, Inc.
Principal Investigator: Philip C Amrein, MD Massachusetts General Hospital
  More Information

Responsible Party: Philip Amrein, MD, Massachusetts General Hospital Identifier: NCT00505700     History of Changes
Other Study ID Numbers: 03-103
Study First Received: July 19, 2007
Last Updated: September 23, 2010

Keywords provided by Massachusetts General Hospital:
acute myeloid leukemia

Additional relevant MeSH terms:
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Neoplasms by Histologic Type
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antibiotics, Antineoplastic
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors processed this record on May 24, 2017